2019 Cell Therapy and Tissue Engineering Market Size, Forecasts, Technologies & Trends Report

DUBLIN, May 20, 2019 /PRNewswire/ -- The "Market for Cell Therapy and Tissue Engineering - Market Size, Forecasts, Technologies & Trends" report has been added to ResearchAndMarkets.com's offering.

This report contains an analysis of developments across the rapidly evolving fields of cell therapy (CT) and tissue engineering (TE), with a focus on competitive dynamics and commercial successes and failures. Cell therapy is the utilization of living cells for the treatment or potential cure of human disease or injury. Tissue engineering (TE) is a field of medicine that is focused on restoring, maintaining, improving, or replacing damaged tissues and organs through the combination of scaffolds, cells, and biologically active molecules. This report highlights important issues across these interrelated fields, including market challenges, economic evaluation, policy improvements, pricing and reimbursement, and rates of global adoption. Because several of the developments in cell therapy and regenerative medicine (RM) are closely related, the report also gives an overview of the regenerative medicine industry.

One of the earliest examples of cell therapy was the transplantation of hematopoietic stem cells (HSCs) in the 1950s from a donor to a recipient to create a bone marrow transplant, which today represents a well-established type of cell therapy practiced worldwide. Newer forms of cell therapy involve the delivery of other cell types to a patients, including CAR-T and CAR-NK cells, mesenchymal stem cells (MSCs), neural stem cells (NSCs), and to a lesser degree, induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), directly reprogrammed cells, and other pluripotent and differentiated cell types.

Because tissue engineering (TE) integrates cellular products with scaffolds, it is integral to the field of cell therapy. These scaffolds are often made using naturally occurring proteins or biocompatible synthetic polymers. Some TE products are made using a protein-based extracellular matrix (ECM) obtained from a donor. The ECM is prepared by removing the cells by a process called decellularization. Cells and growth factors are seeded on to the ECM to develop a tissue or organ.

Cell therapy, gene-modified cell therapy, gene therapy, and tissue engineering are the four pillars of regenerative medicine (RM). These therapies have the potential to favorably change the quality of life and improve the health status of patients suffering from cellular defects, genetic diseases, neurodegenerative diseases, tissue malignancies, and other medical conditions. The combined efforts of research and clinical scientists in academic, translational and industry settings have led us to the development of several approved commercial firsts, such as Glybera, Kymriah, Yescarta, Holoclar, and Luxturna.

Today, the healthcare environment is under great pressure to develop therapies capable of reversing or significantly impacting the progression of serious illnesses. The arrival of regenerative medicine (RM) has been propelled by advances across the cell therapy (CT) and tissue (TE) engineering industries. Regenerative medicines have the potential to transform the healthcare landscape by providing transformative, durable and potentially curative outcomes to human injuries, diseases, and genetic disorders.

With the number of regenerative medicine firms expanding exponentially, over a thousand clinical trials ongoing worldwide (>50% in oncology), and key strategic alliances underway among industry and academic partners, the success of regenerative medicine therapies seems to be a certainty. This report reports the market for regenerative medicine (RM) products approved worldwide, including 44 approvals across the U.S., Europe, South Korea, India, China, Japan, Australia and New Zealand. Additionally, the RM sector saw venture capital investment grow from a mere $200 million in 2010 to a massive $14.6 billion in 2018. This massive investment and market growth in the RM space indicates a future with heavy competition.

Thus, the main objectives of this cell therapy (CT) and tissue engineering (TE) report are to provide the reader with the following details:

• Total global financings in cell therapy and gene-modified cell therapy space.
• Corporate partnerships in cell therapy and gene-modified cell therapy space.
• Private placements and venture financings in cell therapy and gene-modified cell therapy space.
• The history of cell therapy from 1944 to present.
• Potential applications of cell therapy.
• FDA-approved cell therapy products made from human HSCs.
• Leading induced pluripotent stem cell (iPSC) companies.
• Potential applications of iPSCs.
• Various sources of mesenchymal stem cells (MSCs).
• Various clinical applications of mesenchymal stem cells (MSCs).
• Various biologically-active substances secreted by mesenchymal stem cells (MSCs).
• The estimated consumption of MSCs in the cell therapy industry (future projections).
• Other cell types with the potential to disrupt MSC's demand.
• Approved MSC-based cell therapy products in the global market.
• Diseases addressed by neural stem cells in clinical trials.
• Leading companies in neural stem cells space.
• Indications addressed by human embryonic stem cells (hESCs) in clinical trials.
• Leading cell therapy startups.
• Cell therapies with RMAT designation.
• Number of gene-modified cell therapy companies.
• Number of CAR-T cell therapy companies.
• Number of NK cell therapy companies in the world.
• Approved TE products in the global market.
• Number of cell therapy clinical trials.
• Diseases addressed by MSCs in clinical trials.
• Number of clinical trials using MSCs.
• Anticipated clinical events in cell therapy space.
• Number of clinical trials in gene-modified cell therapy space.
• Anticipated developments in cell therapy space in 2019.
• Number of clinical trials in Tissue Engineering (TE) space.
• Approved cell therapy products by geography.
• Approved tissue engineering (TE) products by geography.
• Cell and gene therapy manufacturing capacities in the U.S. and Europe.
• Select CMOs/CDMOs in cell and gene therapy space.
• Projected outsourcing market for the manufacture of cell and gene therapy products.
• Projected growth of cell manufacturing capacity.
• Global market for cell therapy products by geography.
• Global market for tissue-engineered products by geography.
• Profiles of companies that are developing products in cell therapy and tissue engineering spaces.

For companies involved with the commercialization of cell therapy (CT) and tissue engineering (TE) products, this report provides market size determinations, coupled with five-year forecasts and trends. It analyzes emerging market forces, highlights industry partnerships and deal-making, and captures the progression of cell therapy and tissue engineering products across various states of development. With the rapid evolution of this market sector, this global strategic report is your guide to research advances, clinical breakthroughs, and commercialized successes.

Companies Mentioned

• Adaptimmune Therapeutics plc
• Admedus Ltd
• Advanced Bioscience Laboratories, Inc.
• Allogene Therapeutics, Inc
• AlloSource, Inc.
• Ambys Medicines, Inc.
• Anterogen Co., Ltd.
• APAC Biotech Pvt., Ltd.
• apceth Biopharma GmbH
• Asterias Biotherapeutics, Inc
• Atara Biotherapeutics, Inc.
• Athersys, Inc
• ATVIO Biotech Ltd
• AveXis, Inc.
• Avita Medical Ltd
• Batavia Bioscience B.V.
• Bellicum Pharmaceuticals, Inc.
• Betalin Therapeutics
• BioCardia, Inc
• BioReliance Corporation
• Biosolution Co., Ltd.
• Biostage, Inc
• Biovian Oy
• BlueRock Therapeutics
• Bone Therapeutics SA
• Brainstorm Cell Therapeutics, Inc
• Brammer Bio, LLC
• Caladrius Biosciences, Inc
• Carina Biotech
• CARsgen Therapeutics, Ltd
• Cell Cure Neurociences Ltd
• Cell Medica Limited
• Cell Therapy Catapult, Ltd
• Cellerant Therapeutics, Inc.
• Cellular Biomedicine Group, Inc
• Cellular Dynamics International, Inc
• Celonic AG
• Celyad SA
• co-don AG
• Cobra Biologics Ltd.
• Corestem, Inc.
• Cynata Therapeutics, Ltd
• Cytori Therapeutics, Inc
• Dendreon Pharmaceuticals, Inc.
• Enzyvant, Inc.
• Eureka Therapeutics, Inc
• Farmaceutici S.p.A
• Fate Therapeautics, Inc
• Fibrocell Technologies, Inc.
• FUJIFILM Diosynth Biotechnologies, Inc.
• Gamida Cell Ltd.
• GC Cell
• Genzyme Corporation
• Glycostem Therapeutics BV
• Hemostemix, Inc
• Histogenics Corporation
• Humacyte, Inc
• Immusoft Corporation
• Innovative Cellular Therapeutics Co., Ltd
• Iovance Biotherapeutics, Inc.
• J-TEC
• JCR Pharmaceuticals Co., Ltd.
• JW CreaGene Co., Ltd
• Kadimastem Ltd.
• Kaneka Eurogentec S.A.
• KBI Biopharma, Inc.
• Kiadis Pharma N.V
• Kite Pharma, Inc
• Lion TCR Pte. Ltd.
• Lonza Group Ltd
• Magenta Therapeutics, Inc.
• MaxCyte, Inc
• Medigene AG
• MEDIPOST CO., Ltd.
• Mesoblast Limited
• Miromatrix Medical, Inc.
• MolMed S.p.A
• Mustang Bio, Inc
• NantKwest, Inc.
• Neuralstem, Inc
• NexImmune, Inc.
• Nohla Therapeutics, Inc
• Novartis AG
• Novasep Holding SAS
• NuVasive, Inc.
• Orgenesis, Inc
• Orthocell Limited
• Orthofix Medical, Inc.
• Osiris Therapeutics, Inc
• Oxford BioMedica plc
• Paragon Bioservices, Inc
• Pharmicell Co., Ltd
• Pluristem Therapeutics, Inc
• Posedia Therapeutics, Inc
• PROMETHERA Biosciences S.A
• Recipharm AB
• Regenerative Medical System (RMS)
• ReNeuron Group plc
• Richter-Helm BioLogics GmbH & Co. KG
• RoosterBio, Inc
• RoslinCT
• Rubius Therapeutics, Inc.
• Sangamo Therapeutics, Inc
• SCM Lifesciences Co., Ltd.
• Semma Therapeutics Inc
• Sentien Biotechnologies, Inc
• SQZ Biotechnologies
• Stempeutics Research Pvt., Ltd
• Takara Bio, Inc.
• Terumo Corporation
• The Cell and Gene Therapy Catapult
• Triumvira Immunologics USA, Inc.
• TxCell S.A
• Vericel Corporation
• ViaCyte, Inc
• Vibalogics GmbH
• Voyager Therapeutics, Inc
• Waisman Biomanufacturing
• WindMIL Therapeutics, Inc.
• Wuxi App Tec, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/cq0xq4

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com